Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.

Nadia HarbeckDenise WrobelMatthias ZaissJürgen TerhaagDagmar GuthAndrea DistelrathMark-Oliver ZahnRachel WuerstleinAndreas LorenzRupert BartschUrs BreitensteinMichael SchwitterMarija BalicChristian JackischVolkmar MüllerGabriel RinnerthalerMarcus SchmidtKhalil ZamanTimo SchinkötheAnna ReschRoberta ValentiDiana Lüftner

Published in: Breast care (Basel, Switzerland) (2023)

The pattern of anti-HER2 pretreatment observed reflected the current treatment for HER2+/HR+ eBC in Germany, Austria, and Switzerland. These interim results suggest that neratinib as an extended adjuvant is a feasible option after various anti-HER2 pretreatments and that its tolerability can be managed and improved with proactive diarrhea management.

Keyphrases

early stage
clinical trial
combination therapy
positive breast cancer
replacement therapy